FAILDEX失樂園
中文

ARXUM

The business, the turning points, and the decisions behind them.

Founded2019
Event year2024
FundingUS$1.8M

01 / WHAT IT BUILT

What the company did

ARXUM was a Kaiserslautern, Germany-based deep-tech startup founded in 2019 by Markus Jostock and Jens Harig. It built the ARXUM Suite, an industrial blockchain infrastructure and middleware that connected existing IT systems with blockchain-based business logic for secure audit trails, supply chain tracking and cross-company data transfer, later pivoting toward blockchain-based traceability for regulated pharma manufacturing.

02 / ARXUM FAILURE REASONS

Failure factors supported by the current evidence

ARXUM scaled from 3 to 25 employees across Germany, Bulgaria and France and ran 8 publicly funded R&D projects, while its fundraising stayed small (about $1.8M in grants). The company pivoted from manufacturing to GAMP5-compliant pharma traceability and won a Swiss laboratory group as pilot client, but could not build the revenue base to sustain the organization; in January 2024 the Trier court appointed a provisional insolvency administrator, followed by liquidation in April 2024.

03 / EVENT HISTORY

Events in the structured record

  1. Bankruptcy

    North Data’s German commercial-register extract states that by order of the Local Court of Trier (file 23 IN 11/24) dated 24 January 2024 a provisional insolvency administrator was appointed for ARXUM GmbH.

  2. Liquidation

    The same extract lists ARXUM GmbH, Kaiserslautern, as in liquidation (i. L.) with a liquidation event dated 9 April 2024.

04 / CONTEMPORARY REBUILD ASSESSMENT

Difficulty of rebuilding this project today

Material for this section is being gathered and checked. It will appear here once ready.

Rebuild difficultyPending assessmentNot completed
Scoring basisNot completed
ScalabilityPending assessmentNot completed
Scoring basisNot completed

Overall assessment: Not completed

05 / CAUSAL CHAIN

How the factors connect

  1. 01

    Industrial blockchain middleware for manufacturing

  2. 02

    3 to 25 employees; 8 publicly funded R&D projects

  3. 03

    Pivot to GAMP5 pharma traceability; pilot client won

  4. 04

    Insolvency administrator appointed Jan 2024; liquidated Apr 2024